It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
During the early stages of Alzheimer’s disease (AD) in both mouse models and human patients, soluble forms of Amyloid-β 1–42 oligomers (Aβ42o) trigger loss of excitatory synapses (synaptotoxicity) in cortical and hippocampal pyramidal neurons (PNs) prior to the formation of insoluble amyloid plaques. In a transgenic AD mouse model, we observed a spatially restricted structural remodeling of mitochondria in the apical tufts of CA1 PNs dendrites corresponding to the dendritic domain where the earliest synaptic loss is detected in vivo. We also observed AMPK over-activation as well as increased fragmentation and loss of mitochondrial biomass in Ngn2-induced neurons derived from a new APPSwe/Swe knockin human ES cell line. We demonstrate that Aβ42o-dependent over-activation of the CAMKK2-AMPK kinase dyad mediates synaptic loss through coordinated phosphorylation of MFF-dependent mitochondrial fission and ULK2-dependent mitophagy. Our results uncover a unifying stress-response pathway causally linking Aβ42o-dependent structural remodeling of dendritic mitochondria to synaptic loss.
Loss of excitatory synapses occur prior to the formation of amyloid plaques in Alzheimer’s disease. Here the authors show in an animal model that the loss of synapses induced by amyloid-beta oligomers requires over-activation of a stress-response pathway inducing structural remodelling of mitochondria in dendrites of cortical and hippocampal neurons.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details





1 Columbia University Medical Center New York, Department of Neuroscience, New York, USA (GRID:grid.239585.0) (ISNI:0000 0001 2285 2675); Mortimer B. Zuckerman Mind Brain Behavior Institute, New York, USA (GRID:grid.239585.0); Columbia University Medical Center, The Integrated Graduate Program in Cellular, Molecular, and Biomedical Studies, New York, USA (GRID:grid.239585.0) (ISNI:0000 0001 2285 2675)
2 Columbia University Medical Center New York, Department of Neuroscience, New York, USA (GRID:grid.239585.0) (ISNI:0000 0001 2285 2675); Mortimer B. Zuckerman Mind Brain Behavior Institute, New York, USA (GRID:grid.239585.0)
3 Columbia University Medical Center New York, Department of Neuroscience, New York, USA (GRID:grid.239585.0) (ISNI:0000 0001 2285 2675); Mortimer B. Zuckerman Mind Brain Behavior Institute, New York, USA (GRID:grid.239585.0); Columbia University, Department of Biological Sciences, New York, USA (GRID:grid.21729.3f) (ISNI:0000000419368729)
4 Columbia University Medical Center New York, Department of Neuroscience, New York, USA (GRID:grid.239585.0) (ISNI:0000 0001 2285 2675); Mortimer B. Zuckerman Mind Brain Behavior Institute, New York, USA (GRID:grid.239585.0); Oklahoma Medical Research Foundation, Aging & Metabolism Program, Oklahoma City, USA (GRID:grid.274264.1) (ISNI:0000 0000 8527 6890)
5 Columbia University Medical Center, Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, New York, USA (GRID:grid.239585.0) (ISNI:0000 0001 2285 2675)
6 UCB Biopharma, Braine l’Alleud, Belgium (GRID:grid.239585.0)
7 Salk Institute for Biological Studies, Molecular & Cell Biology Laboratory, La Jolla, USA (GRID:grid.250671.7) (ISNI:0000 0001 0662 7144)
8 Université de Paris, CNRS, INSERM, Institut Cochin, Paris, France (GRID:grid.462098.1) (ISNI:0000 0004 0643 431X)
9 Columbia University Medical Center, Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, New York, USA (GRID:grid.239585.0) (ISNI:0000 0001 2285 2675); Columbia University Medical Center, Department of Pathology and Cell Biology, New York, USA (GRID:grid.239585.0) (ISNI:0000 0001 2285 2675)
10 Columbia University Medical Center New York, Department of Neuroscience, New York, USA (GRID:grid.239585.0) (ISNI:0000 0001 2285 2675); Mortimer B. Zuckerman Mind Brain Behavior Institute, New York, USA (GRID:grid.239585.0); Columbia University Medical Center, Kavli Institute for Brain Sciences, New York, USA (GRID:grid.239585.0) (ISNI:0000 0001 2285 2675)